Pacific Biosciences and Oxford Nanopore settle patent dispute
Our client Pacific Biosciences has entered into a five year settlement agreement with Oxford Nanopore to settle a patent infringement dispute in Europe. Partner Simon Kiddle prosecuted the Pacific Biosciences patents at the EPO in this case.
US-based Pacific Biosciences develops and manufactures systems for gene sequencing and is the leader in this field. UK-based Oxford Nanopore develops and sells nanopore sequencing products for the direct, electronic analysis of single molecules.
Under the terms of the agreement Oxford Nanopore will not sell its 2D sequencing products in the UK or in Germany through the end of 2023. In addition, Oxford Nanopore has agreed to dismiss a countersuit it had brought against PacBio in those countries.
Pacific Biosciences had previously filed claims in the High Court of England and Wales and in the District Court of Mannheim, Germany against Oxford Nanopore for infringement
Simon Kiddle is a member of the life sciences patent team and works with Pacific Biosciences on their IP portfolio.